Skip to main content
Top
Published in: International Journal of Hematology 3/2001

01-04-2001 | Case Report

Long-Term Outcome of Treatment With Protocols AL841, AL851, and ALHR88 in Children With Acute Lymphoblastic Leukemia: Results Obtained by the Kyushu-Yamaguchi Children’s Cancer Study Group

Authors: Akinobu Matsuzaki, Eiichi Ishii, Yoshihisa Nagatoshi, Haruhiko Eguchi, Hiroyuki Koga, Fumio Yanai, Hiroko Inada, Keiko Nibu, Yuji Tamai, Kensuke Akiyoshi, Hideki Nakayama, Toshiro Hara, Hiromichi Take, Sumio Miyazaki, Jun Okamura

Published in: International Journal of Hematology | Issue 3/2001

Login to get access
Metadata
Title
Long-Term Outcome of Treatment With Protocols AL841, AL851, and ALHR88 in Children With Acute Lymphoblastic Leukemia: Results Obtained by the Kyushu-Yamaguchi Children’s Cancer Study Group
Authors
Akinobu Matsuzaki
Eiichi Ishii
Yoshihisa Nagatoshi
Haruhiko Eguchi
Hiroyuki Koga
Fumio Yanai
Hiroko Inada
Keiko Nibu
Yuji Tamai
Kensuke Akiyoshi
Hideki Nakayama
Toshiro Hara
Hiromichi Take
Sumio Miyazaki
Jun Okamura
Publication date
01-04-2001
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2001
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/BF02981964

Other articles of this Issue 3/2001

International Journal of Hematology 3/2001 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine